Evidence map

ReviewReviews in endocrine & metabolic disorders2022

Pasireotide-a novel somatostatin receptor ligand after 20 years of use.

Marek Bolanowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

45 papers cite it

2022
2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 35067849